Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Prognostication with circulating tumor DNA: is it ready for prime time?

David M. Kurtz

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 47–52.

https://doi.org/10.1182/hematology.2019000013

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 476–481.

https://doi.org/10.1182/hematology.2019001321

Published: 2019

Journal Articles

Common variable immune deficiency: case studies

Charlotte Cunningham-Rundles

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 449–456.

https://doi.org/10.1182/hematology.2019002062

Published: 2019

Journal Articles

Genomics of aggressive B-cell lymphoma

Allison Rosenthal, Lisa Rimsza

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 69–74.

https://doi.org/10.1182/asheducation-2018.1.69

Published: 2018

Journal Articles

Novel therapies for relapsed/refractory aggressive lymphomas

Jonathon B. Cohen

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 75–82.

https://doi.org/10.1182/asheducation-2018.1.75

Published: 2018

Journal Articles

Novel immunotherapy approaches to follicular lymphoma

Christopher R. Flowers, John P. Leonard, Loretta J. Nastoupil

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 194–199.

https://doi.org/10.1182/asheducation-2018.1.194

Published: 2018

Journal Articles

Challenges and implications of genomics for T-cell lymphomas

Eric D. Jacobsen, David M. Weinstock

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 63–68.

https://doi.org/10.1182/asheducation-2018.1.63

Published: 2018

Journal Articles

Role of the microenvironment across histological subtypes of NHL

Karin Tarte

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 610–617.

https://doi.org/10.1182/asheducation-2017.1.610

Published: 2017

Journal Articles

Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond

Stephen M. Ansell

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 618–621.

https://doi.org/10.1182/asheducation-2017.1.618

Published: 2017

Journal Articles

Developing T-cell therapies for lymphoma without receptor engineering

Melanie Grant, Catherine M. Bollard

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 622–631.

https://doi.org/10.1182/asheducation-2017.1.622

Published: 2017

Journal Articles

Current treatment of double hit and double expressor lymphoma

Patrick M. Reagan, Andrew Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 295–297.

https://doi.org/10.1182/asheducation-2017.1.295

Published: 2017

Journal Articles

Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies

Kieron Dunleavy

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 298–303.

https://doi.org/10.1182/asheducation-2017.1.298

Published: 2017

Journal Articles

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Andrés José María Ferreri

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 565–577.

https://doi.org/10.1182/asheducation-2017.1.565

Published: 2017

Journal Articles

Toward personalized treatment in Waldenström macroglobulinemia

Jorge J. Castillo, Steven P. Treon

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 365–370.

https://doi.org/10.1182/asheducation-2017.1.365

Published: 2017

Journal Articles

Checkpoint inhibition and cellular immunotherapy in lymphoma

Premal Lulla, Helen E. Heslop

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 390–396.

https://doi.org/10.1182/asheducation-2016.1.390

Published: 2016

Journal Articles

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Peter W. M. Johnson

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 316–322.

https://doi.org/10.1182/asheducation-2016.1.316

Published: 2016

Journal Articles

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

Bertrand Coiffier, Clémentine Sarkozy

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 366–378.

https://doi.org/10.1182/asheducation-2016.1.366

Published: 2016

Journal Articles

Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?

Nathan Fowler

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 277–283.

https://doi.org/10.1182/asheducation-2016.1.277

Published: 2016

Journal Articles

Treatment of patients with transformed lymphoma

Silvia Montoto

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 625–630.

https://doi.org/10.1182/asheducation-2015.1.625

Published: 2015

NARROW

Prognostication with circulating tumor DNA: is it ready for prime time?

Indolent lymphomas: pushing the pace with novel agents

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Common variable immune deficiency: case studies

Genomics of aggressive B-cell lymphoma

Novel therapies for relapsed/refractory aggressive lymphomas

Novel immunotherapy approaches to follicular lymphoma

Challenges and implications of genomics for T-cell lymphomas

Role of the microenvironment across histological subtypes of NHL

Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond

Developing T-cell therapies for lymphoma without receptor engineering

Current treatment of double hit and double expressor lymphoma

Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Toward personalized treatment in Waldenström macroglobulinemia

Checkpoint inhibition and cellular immunotherapy in lymphoma

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?

Treatment of patients with transformed lymphoma

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only